The collaboration with RWA Inc. aims to leverage the zkDatabase of Orochi Network to verify and secure real-world data through cryptographic proofs.The collaboration with RWA Inc. aims to leverage the zkDatabase of Orochi Network to verify and secure real-world data through cryptographic proofs.

Orochi Network Partners with RWA Inc. to Bolster RWA Innovation in Web3

blockchain97 main

Orochi Network, a popular blockchain infrastructure provider, has collaborated with RWA Inc., a prominent blockchain entity for RWA tokenization. The collaboration aims to leverage the zkDatabase of Orochi Network to verify and secure real-world data through cryptographic proofs. As the platform disclosed in its announcement on X, the development underscores a key move to guarantee integrity, compliance, and transparency in the diverse RWA solutions.

Hence, the collaboration is anticipated to advance the RWA adoption across the DeFi, enterprise ecosystems, and other blockchain-driven apps.

Orochi Network and RWA Inc.Collaborate to Integrate RWA and Web3 Ecosystems

As a part of this collaboration, the Orochi Network will deliver its cutting-edge zkDatabase technology to RWA Inc. This will permit RWA Inc. to seamlessly validate data while making no compromise on security or scalability. This guarantees the integration of real-world information into the blockchain entities. Thus, this development is set to boost trust among institutions and developers while complying with regulations. The improved verification procedure guarantees compliance and strengthens businesses to efficiently adopt blockchain-led RWA models.

What to Expect from This Partnership for Developers?

According to Orochi Network, the collaboration provides developers with resilient tools to develop scalable as well as secure dApps dealing with real-world assets (RWAs). Therefore, the capability to reach cryptographically proven and verified data decreases risks and expedites product development. Apart from that, it also promotes innovation in diverse sectors, including DeFi lending and enterprise-level blockchain solutions.

Market Opportunity
RealLink Logo
RealLink Price(REAL)
$0,07912
$0,07912$0,07912
-1,77%
USD
RealLink (REAL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale

BullZilla, World Liberty Financial, MoonBull, La Culex, and Polkadot (DOT) are taking the spotlight among emerging and established crypto projects […] The post 5 High-Growth Cryptos for 2025: BullZilla Tops the Charts as the Best 100x Crypto Presale appeared first on Coindoo.
Share
Coindoo2025/10/18 08:15
Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26